MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Catechin

CAS No. : 154-23-4

MCE 站：Catechin

产品活性：Catechin ((+)-Catechin) 抑制环加氧酶-1 (COX-1) , IC₅₀ 为 1.4 μM。

研究领域：Immunology/Inflammation  |  Apoptosis  |  Anti-infection  |  Metabolic Enzyme/Protease

作用靶点：COX  |  Apoptosis  |  Influenza Virus  |  Endogenous Metabolite

In Vitro: Catechin ((+)-Catechin) exhibits >95% inhibitory activity at 70 μg/mL against cyclooxygenase-1 (COX-1) with an IC₅₀ of 1.4 μM.
A dose-dependent reduction in color is observed after 24 hours of treatment with Catechin, and 54.76% of the cells are dead at the highest concentration of Catechin tested (160 μg/mL) whereas the IC₅₀ of Catechin is achieved at 127.62 μg/mL Catechin. A dose- and time-dependent increase in the induction of apoptosis is observed when MCF-7 cells are treated with Catechin. When compare to the control cells at 24 hours, 40.7 and 41.16% of the cells treated with 150 μg/mL and 300 μg/mL Catechin, respectively, undergo apoptosis. The expression levels of Caspase-3, -8, and -9 and p53 in MCF-7 cells treated with 150 μg/mL Catechin for 24 h increase by 5.81, 1.42, 3.29, and 2.68 fold, respectively, as compare to the levels in untreated control cells.

In Vivo: Animals treated with Catechin ((+)-Catechin) at the lowest tested dose, i.e., 50 mg/kg, p.o. have spent comparatively more time in exploring the novel object in the choice trial, however, the difference is not statistically significant. Catechin prevents the time-induced episodic memory deficits in a dose-dependent manner, the most effective being 200 mg/kg, p.o.. Treatment with Catechin prevents the rise in MPO level compare to DOX alone treatment group (21.98±9.44 and 36.76±4.39% in the hippocampus and the frontal cortex respectively).

相关产品：Natural Product Library Plus  |  Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Anti-Infection Compound Library  |  Apoptosis Compound Library  |  Immunology/Inflammation Compound Library  |  Metabolism/Protease Compound Library  |  Natural Product Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Antiviral Compound Library  |  Human Endogenous Metabolite Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Anti-COVID-19 Compound Library  |  Traditional Chinese Medicine Monomer Library  |  FDA Approved & Pharmacopeial Drug Library  |  Flavonoids Library  |  MG-132  |  Rapamycin  |  3-Methyladenine  |  LY294002  |  Doxorubicin hydrochloride  |  Bafilomycin A1  |  Paclitaxel  |  Y-27632 dihydrochloride  |  Acetylcysteine  |  Angiotensin II human  |  SP600125  |  5-Fluorouracil  |  Staurosporine  |  Bortezomib  |  Tamoxifen  |  2-Deoxy-D-glucose  |  Gemcitabine  |  U0126-EtOH  |  Verteporfin  |  Decitabine  |  Actinomycin D  |  Temozolomide  |  ATP  |  BAY 11-7082  |  Etoposide  |  Mitomycin C  |  CCCP  |  Retinoic acid  |  DAPT

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。